D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 81 Citations 22,182 291 World Ranking 9265 National Ranking 5064

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Surgery

Christopher H. Crane mostly deals with Surgery, Radiation therapy, Internal medicine, Pancreatic cancer and Chemoradiotherapy. His studies in Surgery integrate themes in fields like Cancer, Colorectal cancer, Primary tumor and Radiology. His Radiation therapy research integrates issues from Fluorouracil, Chemotherapy, Rectum, Capecitabine and Survival analysis.

His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Oncology. His study looks at the relationship between Pancreatic cancer and fields such as Pancreatectomy, as well as how they intersect with chemical problems. His Adenocarcinoma research includes themes of Combined Modality Therapy, Surgical oncology and Pancreatic disease.

His most cited work include:

  • Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy (600 citations)
  • Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. (580 citations)
  • Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head (574 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Internal medicine, Radiation therapy, Oncology, Surgery and Pancreatic cancer. His work on Gemcitabine, Adenocarcinoma and Capecitabine as part of general Internal medicine research is frequently linked to In patient, bridging the gap between disciplines. His Radiation therapy research incorporates elements of Nuclear medicine, Anal cancer and Chemotherapy.

His work in Oncology tackles topics such as Carcinoma which are related to areas like Survival rate. His studies in Surgery integrate themes in fields like Neoadjuvant therapy and Cancer, Colorectal cancer. His studies deal with areas such as Pancreatectomy, Pancreatic disease and Clinical trial as well as Pancreatic cancer.

He most often published in these fields:

  • Internal medicine (50.80%)
  • Radiation therapy (43.88%)
  • Oncology (41.49%)

What were the highlights of his more recent work (between 2014-2021)?

  • Internal medicine (50.80%)
  • Oncology (41.49%)
  • Radiation therapy (43.88%)

In recent papers he was focusing on the following fields of study:

Christopher H. Crane mainly focuses on Internal medicine, Oncology, Radiation therapy, Radiology and Surgery. His research ties Gastroenterology and Internal medicine together. Christopher H. Crane has researched Oncology in several fields, including Survival rate, Cancer, Esophageal cancer and CA19-9.

His biological study spans a wide range of topics, including Proportional hazards model, Intrahepatic Cholangiocarcinoma, Chemotherapy and Nuclear medicine. His Radiology research includes elements of Prospective cohort study and Anal Squamous Cell Carcinoma. His Surgery study combines topics from a wide range of disciplines, such as Recurrent Rectal Cancer, Colorectal cancer, Anal cancer and Toxicity.

Between 2014 and 2021, his most popular works were:

  • Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. (204 citations)
  • Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline (182 citations)
  • Hilar Cholangiocarcinoma: expert consensus statement (161 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Surgery

Internal medicine, Oncology, Radiation therapy, Surgery and Carcinoma are his primary areas of study. His study in Gemcitabine, Pancreatic cancer, Chemoradiotherapy, Capecitabine and Odds ratio falls under the purview of Internal medicine. His Oncology research integrates issues from Survival rate, Cancer, Adenocarcinoma and Pancreatectomy.

His Survival rate study integrates concerns from other disciplines, such as Neoadjuvant therapy, Combined Modality Therapy, Phases of clinical research and Lymph node. His Radiation therapy research includes themes of Medical physics, Proportional hazards model and Nuclear medicine. His Surgery study frequently involves adjacent topics like Recurrent Rectal Cancer.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong.
Annals of Surgical Oncology (2006)

802 Citations

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

Matthew H.G. Katz;Peter W.T. Pisters;Douglas B. Evans;Charlotte C. Sun.
Journal of The American College of Surgeons (2008)

761 Citations

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

Douglas B. Evans;Gauri R. Varadhachary;Christopher H. Crane;Charlotte C. Sun.
Journal of Clinical Oncology (2008)

749 Citations

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

Patrick J. Loehrer;Yang Feng;Higinia Cardenes;Lynne Wagner.
Journal of Clinical Oncology (2011)

729 Citations

Pancreaticoduodenectomy with vascular resection: margin status and survival duration

Jennifer F. Tseng;Chandrajit P. Raut;Jeffrey E. Lee;Peter W.T. Pisters.
Journal of Gastrointestinal Surgery (2004)

602 Citations

Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

Chandrajit P. Raut;Jennifer F. Tseng;Jennifer F. Tseng;Charlotte C. Sun;Huamin Wang.
Annals of Surgery (2007)

600 Citations

Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

Gauri R. Varadhachary;Robert A. Wolff;Christopher H. Crane;Charlotte C. Sun.
Journal of Clinical Oncology (2008)

483 Citations

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

Matthew Harold Katz;Matthew Harold Katz;Huamin Wang;Jason B Fleming;Charlotte C Sun.
Annals of Surgical Oncology (2009)

454 Citations

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

T. M. Breslin;K. R. Hess;D. B. Harbison;M. E. Jean.
Annals of Surgical Oncology (2001)

453 Citations

Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response

Jaffer A. Ajani;Kathryn Winter;Gordon S. Okawara;John H. Donohue.
Journal of Clinical Oncology (2006)

449 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Christopher H. Crane

Joseph M. Herman

Joseph M. Herman

Johns Hopkins University School of Medicine

Publications: 107

Douglas B. Evans

Douglas B. Evans

Medical College of Wisconsin

Publications: 98

Timothy M. Pawlik

Timothy M. Pawlik

The Ohio State University Wexner Medical Center

Publications: 82

Jason B. Fleming

Jason B. Fleming

The University of Texas MD Anderson Cancer Center

Publications: 73

Christopher L. Wolfgang

Christopher L. Wolfgang

New York University

Publications: 71

Jeffrey E. Lee

Jeffrey E. Lee

The University of Texas MD Anderson Cancer Center

Publications: 68

Jaffer A. Ajani

Jaffer A. Ajani

The University of Texas MD Anderson Cancer Center

Publications: 65

Bruce D. Minsky

Bruce D. Minsky

The University of Texas MD Anderson Cancer Center

Publications: 59

Albert C. Koong

Albert C. Koong

The University of Texas MD Anderson Cancer Center

Publications: 57

Christopher G. Willett

Christopher G. Willett

Duke University

Publications: 56

Laura A. Dawson

Laura A. Dawson

Princess Margaret Cancer Centre

Publications: 52

Claudio Bassi

Claudio Bassi

University of Verona

Publications: 50

Markus W. Büchler

Markus W. Büchler

University Hospital Heidelberg

Publications: 49

Robert A. Wolff

Robert A. Wolff

The University of Texas MD Anderson Cancer Center

Publications: 48

Herbert J. Zeh

Herbert J. Zeh

University of Pittsburgh

Publications: 48

Thomas Brunner

Thomas Brunner

University of Konstanz

Publications: 47

Trending Scientists

Peter Buneman

Peter Buneman

University of Edinburgh

Klaus Schmidt

Klaus Schmidt

University of Vienna

Martin Alexander

Martin Alexander

Cornell University

Minoru Kanehisa

Minoru Kanehisa

Kyoto University

Markus Hauck

Markus Hauck

University of Freiburg

Britt-Marie Sjöberg

Britt-Marie Sjöberg

Stockholm University

Fotis C. Kafatos

Fotis C. Kafatos

Imperial College London

C. Mark Moore

C. Mark Moore

University of Southampton

Henry J. Waldvogel

Henry J. Waldvogel

University of Auckland

Suzanne M. Miller

Suzanne M. Miller

Fox Chase Cancer Center

Marcela Raffaelli

Marcela Raffaelli

University of Illinois at Urbana-Champaign

George R. Saade

George R. Saade

The University of Texas Medical Branch at Galveston

Ann Williamson

Ann Williamson

University of New South Wales

Paul W. Speer

Paul W. Speer

Vanderbilt University

R. P. Lin

R. P. Lin

University of California, Berkeley

Something went wrong. Please try again later.